Stock Events

Stock Events

Indaptus Therapeutics 

$3.29
22
-$0.26-7.32% 15:38 Today

Statistics

Day High
3.65
Day Low
3.28
52W High
14
52W Low
1.06
Volume
262,137
Avg. Volume
-
Mkt Cap
5.76M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-9.24
-6.24
-3.23
-0.23
Expected EPS
-1.57
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-30.04MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INDP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap25.38B
Moderna is a leader in mRNA technology, which is a platform that can potentially compete with Indaptus Therapeutics' approach to immunotherapy and vaccine development.
BioNTech
BNTX
Mkt Cap22.98B
BioNTech, similar to Moderna, specializes in mRNA technology for vaccines, directly competing in the immunotherapy space.
Novavax
NVAX
Mkt Cap1.5B
Novavax is involved in the development of vaccines for infectious diseases, which could compete with Indaptus Therapeutics' vaccine programs.
Gilead Sciences
GILD
Mkt Cap153.66B
Gilead Sciences is a biopharmaceutical company that focuses on antiviral drugs and other treatments that could compete with Indaptus Therapeutics' therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap63.95B
Regeneron Pharmaceuticals is known for its innovation in creating monoclonal antibodies, which could be in direct competition with any antibody-based therapies developed by Indaptus.
AMGEN
AMGN
Mkt Cap182.21B
Amgen focuses on human therapeutics, including treatments in immunology, which could overlap with Indaptus Therapeutics' focus areas.
Pfizer
PFE
Mkt Cap143.68B
Pfizer is a large pharmaceutical company with a broad portfolio, including vaccines and immunotherapies that could compete with Indaptus Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap549.78B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments and vaccines that could compete with Indaptus' offerings.
Astrazeneca
AZN
Mkt Cap271.29B
AstraZeneca is involved in the development of vaccines and treatments for infections and diseases, potentially competing with Indaptus Therapeutics.
Merck
MRK
Mkt Cap281.24B
Merck & Co. is known for its vaccines and anti-infective treatments, which could directly compete with Indaptus Therapeutics' development programs.

About

Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Show more...
CEO
Dr. Michael J. Newman Ph.D.
Employees
7
Country
United States
ISIN
US45339J2042

Listings

BOATS
BOATS
INDP.BOATS
XNAS
US
INDP

0 Comments

Share your thoughts

FAQ

What is Indaptus Therapeutics stock price today?▼
The current price of INDP is $3.29 USD — it has decreased by -7.32% in the past 24 hours. Watch Indaptus Therapeutics stock price performance more closely on the chart.
What is Indaptus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Indaptus Therapeutics stocks are traded under the ticker INDP.
Is Indaptus Therapeutics stock price growing?▼
INDP stock has fallen by -14.74% compared to the previous week, the month change is a +172.54% rise, over the last year Indaptus Therapeutics has showed a -67.73% decrease.
What is Indaptus Therapeutics market cap?▼
Today Indaptus Therapeutics has the market capitalization of 5.76M
When is the next Indaptus Therapeutics earnings date?▼
Indaptus Therapeutics is going to release the next earnings report on August 17, 2026.
What were Indaptus Therapeutics earnings last quarter?▼
INDP earnings for the last quarter are -0.23 USD per share, whereas the estimation was -1.87 USD resulting in a +87.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Indaptus Therapeutics revenue for the last year?▼
Indaptus Therapeutics revenue for the last year amounts to 0 USD.
What is Indaptus Therapeutics net income for the last year?▼
INDP net income for the last year is -30.04M USD.
How many employees does Indaptus Therapeutics have?▼
As of June 25, 2026, the company has 7 employees.
In which sector is Indaptus Therapeutics located?▼
Indaptus Therapeutics operates in the Health & Wellness sector.
When did Indaptus Therapeutics complete a stock split?▼
The last stock split for Indaptus Therapeutics was on June 27, 2025 with a ratio of 1:28.
Where is Indaptus Therapeutics headquartered?▼
Indaptus Therapeutics is headquartered in New York, United States.